OncoMatch/Clinical Trials/NCT07276360
Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda
Is NCT07276360 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cisplatin for cervical cancer.
Treatment: Cisplatin — This phase II trial compares the effect of hypofractionated radiotherapy (HFRT) to conventional fractionated radiotherapy (CFRT) when given in combination with cisplatin and brachytherapy in patients with stage IB3, II, or III cervical cancer. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. CFRT delivers the total dose of radiation over the amount of time according to standard practice. HFRT delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. HFRT shortens treatment duration and may reduce costs and may improve the completion rates. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. HFRT may be safe, tolerable, and/or as effective as CFRT when given in combination with cisplatin and brachytherapy in treating patients with stage IB3, II or III cervical cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB, IIIC
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: pelvic or abdominal radiotherapy
Prior pelvic or abdominal radiotherapy
Cannot have received: hysterectomy
Prior hysterectomy
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500 cells/mm^3; Platelets ≥ 100,000 cells/mm^3; Hemoglobin ≥ 9.0 g/dL; Leukocyte count ≥ 4,000 cells/mm^3
Kidney function
Creatinine clearance > 60 mL/mins (Cockcroft-Gault equation for women)
Liver function
AST and ALT < 3 x ULN; total bilirubin < 2 x ULN unless attributed to ART
Absolute neutrophil count ≥ 1,500 cells/mm^3; Platelets ≥ 100,000 cells/mm^3; Hemoglobin ≥ 9.0 g/dL; Leukocyte count ≥ 4,000 cells/mm^3; Creatinine clearance > 60 mL/mins; AST and ALT < 3 x ULN; Total bilirubin < 2 x ULN unless attributed to ART
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify